These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15742978)

  • 1. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
    Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
    Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
    Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
    Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.
    Kirchheiner J; Ufer M; Walter EC; Kammerer B; Kahlich R; Meisel C; Schwab M; Gleiter CH; Rane A; Roots I; Brockmöller J
    Pharmacogenetics; 2004 Jan; 14(1):19-26. PubMed ID: 15128047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes.
    Kammerer B; Kahlich R; Ufer M; Schenkel A; Laufer S; Gleiter CH
    Anal Bioanal Chem; 2005 Nov; 383(6):909-17. PubMed ID: 16237546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.
    Sandberg M; Yasar U; Strömberg P; Höög JO; Eliasson E
    Br J Clin Pharmacol; 2002 Oct; 54(4):423-9. PubMed ID: 12392591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
    Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
    Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Vliet M; van Schaik RH; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Pharmacogenetics; 2004 Jan; 14(1):27-33. PubMed ID: 15128048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
    Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.
    Abduljalil K; Lazar S; Natanzon M; Wu W; Zadoyan G; Steffens B; Kohl V; Mörike K; Tomalik-Scharte D; Stingl J; Schwab M; Harenberg J; Gleiter C; Fuhr U
    Clin Pharmacokinet; 2013 May; 52(5):359-71. PubMed ID: 23519598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.
    Yasar U; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
    Eur J Clin Pharmacol; 2001 Dec; 57(10):729-35. PubMed ID: 11829203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
    Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
    Thijssen HH; Ritzen B
    Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.